Abstract
The purpose of this study was to evaluate the biochemical parameters and cytokines levels in infected Egyptian patient.This study was conducted on 32 patients. 25 of them were suffering from chronic HCV and the other 7 males are selfreportedhealthy volunteers. They were classified as the following: Group I (control healthy group), Group II (HCV-nontreated group) Group III- Group VI (HCV-treated with 12,24,36,48 ampoule of interferon). The obtained results showeda significant increase in the activities of serum liver marker enzymes ALT, AST and ALP, cytokines Il2, Il4 and Il10,also a significant increase was observed in serum Ferritin and Alpha feto protein. On the other hand, a significantdecrease in both sera total protein and albumin level. Whereas administration of combination of Pegylated IFN-α2b andRibavarin significantly improved the alert in the biochemical parameters. These results suggested that, combinationtherapy of both peg-interferon and ribavirin, emphasizing the influence of these compounds for patient with HCV,possibly preventing alteration of enzymes of liver activities. Because peg-interferon treatment can reduce liver injuryand anti-inflammatory effect, as well as by decreasing plasma cytokine as cytokines, is present in patients with HCVliver disease. Furthermore, treatment with IFN-α diminishes the Th2 cytokine response. Thus, modulation of T- cellfunction and cytokine production may be one mechanism whereby IFN-α therapy results in reduced viral burden
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.